Combination of Atezolizumab, Bevacizumab, and Stereotactic Body Radiotherapy for Treating Advanced Liver Cancer

What this Trial Is About

Researchers are evaluating the combination of atezolizumab and bevacizumab with stereotactic body radiotherapy SBRT for patients with advanced hepatocellular carcinoma. This study aims to improve the treatment response rate of the current first-line chemotherapy, which has shown low response rates. Participants have advanced liver cancer that cannot be operated on and are eligible for this combination therapy. Participants will receive SBRT targeting one to five sites of primary or metastatic cancer lesions within two months before or after starting the atezolizumab-bevacizumab combination therapy. The study includes several visits screening, during and after SBRT, chemotherapy cycles, and follow-up visits lasting up to 36 months to monitor treatment effects and safety. During the study, participants will undergo medical history reviews, physical exams, imaging tests like CT or MRI, blood tests including tumor markers and biomarkers, stool microbiota analysis, and quality of life questionnaires. Researchers will monitor adverse events and assess progression-free survival at 6 months as the primary outcome, alongside secondary outcomes such as overall survival, tumor response, and safety over 36 months.

Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma